The FDA has granted breakthrough therapy designation (BTD) to sofetabart mipitecan (LY4170156) for the treatment of patients ...
The NCCN guidelines now include MammaPrint for identifying HR+/HER2- early-stage breast cancer patients who may benefit from ...
Intismeran autogene with pembrolizumab shows a 49% reduction in recurrence or death risk in high-risk resected melanoma ...
Pelareorep combined with atezolizumab achieved a 29% ORR in heavily pretreated metastatic SCAC patients, significantly ...
The FDA has accepted the supplemental Biologics License Application (BLA) for ropeginterferon alfa-2b-njft (Besremi), a ...
AI is transforming oncology by improving early detection, diagnosis, and treatment personalization through advanced data ...
Rebecca Siegel highlights alarming cancer disparities among American Indian, Alaska Native, and Black populations, ...
Zenocutuzumab (Bizengri) continued to provide sustained clinical benefit and disease control in patients with advanced NRG1 fusion-positive ( NRG1 +) pancreatic adenocarcinoma (PDAC) and ...
Early results from the ongoing QUILT-106 clinical trial (NCT06334991) show that the treatment combination of CD19 chimeric antigen receptor natural killer (CAR-NK) cells with rituximab (Rituxan) can ...
Gedatolisib's NDA for advanced breast cancer treatment has been accepted by the FDA, with a priority review and a PDUFA date set for July 17, 2026. The drug is intended for HR+/HER2–, PIK3CA wild-type ...
In the evolving landscape of metastatic colorectal cancer, managing patients with RAS/BRAF wild-type tumors remains a ...
Patients were randomly assigned on a 1:1 basis to receive teclistamab as monotherapy or physician’s choice of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback